Search Results
May 28, 2026, 09:00 ET China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy
Porton Advanced. From the U.S. to China, Porton Advanced's global, end-to-end CDMO platform has consistently provided a solid foundation for the China-US dual filing strategy of innovative drugs.As the exclusive CDMO partner for the project, Porton Advanced provided comprehensive bacteria CMC services,
More news about: Porton Advanced
May 28, 2026, 07:08 ET China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy
Porton AdvancedPorton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has dual-headquarters in Cranbury, New Jersey, and Suzhou, China, providing end-to-end CDMO solutions for ATMPs including plasmids, viral vectors, cell therapy and nucleic acid
More news about: Porton Advanced
May 28, 2026, 07:03 ET Veeva Quality Cloud Advances Manufacturing Operations for Kindeva
Global CDMO will unify sites on single quality platform for greater efficiency and scalabilityPLEASANTON, Calif., May 28, 2026 /PRNewswire/ -- Veeva
More news about: Veeva Systems
May 28, 2026, 07:03 ET Veeva Quality Cloud Advances Manufacturing Operations for Kindeva
Global CDMO will unify sites on single quality platform for greater efficiency and scalabilityBARCELONA, Spain, May 28, 2026 /PRNewswire/ -- Veeva
More news about: Veeva Systems
May 28, 2026, 05:45 ET 코든파마, 암비오팜 인수...글로벌 펩타이드 API 생산 역량 확대
스케일업 경로, 지역 및 글로벌 공급 모델 측면에서 고객 선택지가 넓어져 코든파마의 펩타이드 CDMO 역량도 강화될 전망이다.바젤, 스위스, 2026년 5월 28일 /PRNewswire/ -- 글로벌 선도 위탁개발생산(CDMO) 기업 코든파마가 미국에 본사를 둔 펩타이드 API CDMO 기업 암비오팜 인수 계약을 체결했다고 5월 27일 발표했다.
More news about: CordenPharma
May 27, 2026, 09:19 ET GBI Biomanufacturing Appoints Chandra Kelley as Chief Business Officer
May 27, 2026 /PRNewswire/ -- GBI Biomanufacturing, Inc., (GBI) a leading biologics Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Chandra Kelley as Chief Business Officer (CBO). In this role, Kelley will lead the company's commercial
More news about: GBI Biomanufacturing
May 27, 2026, 09:00 ET NorthStar and QSA Global Announce Multi-Year Strategic Partnership to Strengthen Actinium-225 Supply Chain for Targeted Alpha Therapies
actinium-225 (n.c.a. Ac-225) using electron-accelerator technology. The Company's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance
More news about: QSA Global, Inc.
May 27, 2026, 09:00 ET NorthStar and QSA Global Announce Multi-Year Strategic Partnership to Strengthen Actinium-225 Supply Chain for Targeted Alpha Therapies
actinium-225 (n.c.a. Ac-225) using electron-accelerator technology. The Company's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance
More news about: QSA Global, Inc.
May 27, 2026, 09:00 ET NorthStar und QSA Global kündigen eine mehrjährige strategische Partnerschaft zur Stärkung der Actinium-225-Lieferkette für gezielte Alpha-Therapien an
Hilfe der Elektronenbeschleunigertechnologie. Die Dienstleistungseinheit des Unternehmens für radiopharmazeutische Auftragsentwicklung und -herstellung (CDMO) bietet maßgeschneiderte Serviceangebote und spezialisiertes radiopharmazeutisches Fachwissen, um biopharmazeutische Unternehmen dabei zu unterstützen,
More news about: QSA Global, Inc.
May 27, 2026, 09:00 ET NorthStar y QSA Global anuncian una alianza para fortalecer la cadena de suministro de actinio-225
(n.c.a. Ac-225) utilizando tecnología de aceleradores de electrones. La unidad de servicios de Organización de Desarrollo y Fabricación por Contrato (CDMO) de radiofármacos de la compañía ofrece servicios personalizados y experiencia especializada en radiofármacos para ayudar a las empresas biofarmacéuticas
More news about: QSA Global, Inc.
May 27, 2026, 09:00 ET NorthStar et QSA Global annoncent un partenariat stratégique pluriannuel visant à renforcer la chaîne d'approvisionnement en actinium-225 pour les thérapies alpha ciblées
utilisant la technologie de l'accélérateur d'électrons. L'unité de services Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) de la société propose des services personnalisés et une expertise radiopharmaceutique spécialisée afin d'aider les sociétés biopharmaceutiques à faire
More news about: QSA Global, Inc.
May 27, 2026, 08:00 ET Minaris Expands Rapid Mycoplasma Detection Services with bioMérieux's BIOFIRE® Platform to Reduce Turnaround Time for Release and In-Process Testing
May 27, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced an expanded rapid mycoplasma testing capability within its Minaris Advanced Testing division
More news about: Minaris Advanced Therapies, LLC
May 27, 2026, 07:21 ET CordenPharma adquiere AmbioPharm para ampliar su capacidad global de producción de principios activos peptídicos
/PRNewswire/ -- CordenPharma, una organización líder mundial en desarrollo y fabricación por contrato (CDMO, por sus siglas en inglés), anuncia hoy que ha llegado a un acuerdo para adquirir AmbioPharm, una CDMO de principios activos peptídicos con sede en Estados Unidos.
More news about: CordenPharma
May 27, 2026, 07:17 ET CordenPharma erwirbt AmbioPharm zur Erweiterung der weltweiten Peptid-API-Kapazität
/PRNewswire/ -- CordenPharma, ein weltweit führendes Auftragsentwicklungs- und -herstellungsunternehmen (CDMO), gab heute bekannt, dass es eine Vereinbarung zur Übernahme von AmbioPharm, einem CDMO für Peptid-Wirkstoffe mit Hauptsitz in den USA, getroffen hat.
More news about: CordenPharma
May 27, 2026, 07:12 ET CordenPharma acquiert AmbioPharm pour accroître sa capacité mondiale de production d'API peptidiques
/PRNewswire/ -- CordenPharma, une organisation mondiale de développement et de fabrication sous contrat (CDMO) de premier plan, annonce aujourd'hui qu'elle a conclu un accord pour acquérir AmbioPharm, une CDMO d'API de peptides basée aux États-Unis.
More news about: CordenPharma
May 27, 2026, 01:00 ET CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity
/PRNewswire/ -- CordenPharma, a leading global Contract Development and Manufacturing Organization (CDMO), today announces that it has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO.
More news about: CordenPharma
May 27, 2026, 01:00 ET CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity
/PRNewswire/ -- CordenPharma, a leading global Contract Development and Manufacturing Organization (CDMO), today announces that it has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO.
More news about: CordenPharma
May 26, 2026, 10:08 ET ILC Dover Expands Life Sciences Presence with Water for Injection (WFI) and Custom Chemical Solutions
compliant, high‑purity liquid manufacturing and fulfillment across the life sciences.For more information about ILC Dover's WFI capabilities and CDMO services, visit
More news about: ILC Dover
May 26, 2026, 10:08 ET ILC Dover amplía su presencia en ciencias biológicas con agua para inyección (WFI) y soluciones químicas personalizadas
pureza y conformidad en todas las ciencias biológicas.Para obtener más información sobre las capacidades de WFI de ILC Dover y los servicios de CDMO, visite
More news about: ILC Dover
May 26, 2026, 06:00 ET AVANT BIO Names Maik W. Jornitz and Lukas Utiger as Operating Advisors to Strengthen Portfolio Operational Support and Strategic Growth
program at IMD Business School in Lausanne, Switzerland.Lukas Utiger brings more than three decades of executive leadership across the global CDMO and bioprocessing landscape. He spent 20 years at Lonza Group AG, where he progressed from Head of Research and Development for Exclusive Synthesis
More news about: AVANT BIO LLC
May 26, 2026, 00:00 ET WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing
WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that its drug substance facility (MFG23) located in Suzhou has received Good Manufacturing Practices (GMP) certification from Brazil's
More news about: WuXi Vaccines
May 22, 2026, 07:00 ET AVISTA HEALTHCARE PARTNERS SIGNS DEFINITIVE AGREEMENT TO ACQUIRE SANOTACT GROUP
development, manufacturing, and commercialization of VMS products. The Company operates a diversified business model combining a scaled, full-service CDMO platform with capabilities across all major VMS dosage forms and a portfolio of branded VMS products, including sanotact®, an established German VMS
More news about: Avista Healthcare Partners
May 20, 2026, 12:48 ET /C O R R E C T I O N -- Pegasus/PRN Pharmacal/
cats, dogs, and horses and is owned by PBI-Gordon Companies, Inc. Pegasus provides full-service Contract Development and Manufacturing Organization (CDMO) focusing on the development and manufacturing with full turn-key technical services in an FDA-registered facility that is in compliance with current
More news about: Pegasus/PRN Pharmacal
May 20, 2026, 10:00 ET UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)
services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet
More news about: Upsher-Smith Laboratories, LLC
May 20, 2026, 08:00 ET Pinnaql Acquires Pharma Resource Group, Expanding Engineering, Validation, Tech Transfer, and Manufacturing Support for Life Sciences Clients
commitment as a full-lifecycle partner for its clients.Together, the combined organizations are equipped to support pharmaceutical, biotechnology, and CDMO clients through every phase of product development and commercialization — delivering technically rigorous, inspection-ready solutions aligned with
More news about: Pinnaql